Author of

• 35693

  +

  P52 - Staging - Prognosis and Staging (ID 186)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Staging
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35694

    +

    P52.01 - Lepidic Component Identifies a Subgroup of Lung Adenocarcinoma with a Distinctive Prognosis: A Chinese Population-based Multicenter Study (ID 2496)

    00:00 - 00:00  |  Presenting Author(s): Erjia Zhu
    • Abstract
    • Slides

    Introduction
    

    The aim was to investigate the prognostic value of the lepidic component in patients with lung adenocarcinoma (LUAD).

    Methods
    

    We retrospectively investigated 1,719 surgically resected LUAD samples classified as p-stage T1a-T2N0M0 according to the eighth edition of Lung Cancer Stage Classification.

    Results
    

    Of the cases, 863 (50%) had a lepidic component. Multivariate analysis revealed that lepidic component presence was an independent prognostic factor for prolonged recurrence-free survival (RFS; P < 0.001) and overall survival (OS; P < 0.001). Furthermore, lepidic ratios (LR) > 50%, between 25% and 50% or ≤ 25% were confirmed to be independent prolonged survival predictors. No survival differences were observed among patients with LUAD with LR > 50%, between 25% and 50% or ≤ 25% (RFS, P = 0.342; OS, P = 0.256). When accounting for lepidic component presence, neither T stage nor pathological subtype was associated with the prognosis of LUAD with a lepidic component. The 5-year OS rates of patients with LUAD with a lepidic component were 90% regardless of the T stage or pathological subtype, and these survival rates were significantly better than those of patients with LUAD without a lepidic component in the corresponding T stage or pathological subtype.

    Conclusion
    

    Lepidic component presence identifies a LUAD subgroup with an excellent prognosis independent of the LR, pathological subtype and pathological T classification. Considering lepidic component presence may improve prognostic predictions for patients with LUAD.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.